Interleukin Genetics to Present at Upcoming Biotech Industry Meetings

WALTHAM, Mass., May 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Effective Use of Biomarkers in Early to Late-Stage Drug Development: How to Improve Efficacy and Commercial Success" at the BIO International Convention, being held May 3-6, 2010 in Chicago, IL.  The panel discussion will be held Wednesday, May 5, from 8-9:30 a.m. CDT in Room N426B at McCormick Place. Co-presenting at BIO alongside Interleukin Genetics will be PGxHealth LLC, a Clinical Data company, Merck Research Laboratories and Nordic Biosciences.

In addition, Interleukin Genetics will present at the Rodman & Renshaw 6th Annual Global Healthcare Conference, to be held May 16-18, 2010 at the Grosvenor House Hotel, London, UK. Mr. Bender will present on behalf of the company at 3:15 p.m. GMT in the Aldford Suite on Monday, May 17. A live audio and webcast of the corporate presentation will be available. The presentation will be archived for 90 days and available on the Investor Relations section of the Interleukin Genetics website.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health brand including Bone Health, Weight Management, Heart Health and Nutritional Needs.  The Company is headquartered in Waltham, MA.  For more information please visit www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.